Patents by Inventor Barry Maxwell Wagland

Barry Maxwell Wagland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5942413
    Abstract: Disclosed is a substantially purified antigen derived from a first species of parasitic nematodes, which antigen is capable of providing protection to a host from parasitism infestation by a second nematode species, which may be the same as or different from the first nematode species, following vaccination of the host with the antigen, characterized in that the antigen is proteinaceous, has a pI between 3.8 and 4.4, can be bound by lentil lectin and Helix promatia and has a molecular weight of approximately 45 kD as determined by SDS-PAGE.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 24, 1999
    Assignees: Biotech Australia PTY Limited, Commonwealth Scientific and Industrial Research Organization
    Inventors: Phillip John Sharp, Barry Maxwell Wagland, Gary Stewart Cobon
  • Patent number: 5871738
    Abstract: Disclosed is a substantially purified antigen derived from a first parasitic nematode species which, when administered to a host animal, is capable of protecting the host animal from infestation by a second parasitic nematode species, wherein the first and second parasitic nematode species may be the same or different, and the antigen has an apparent molecular weight of 40 kD as determined by SDS-PAGE under reducing conditions.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: February 16, 1999
    Assignees: Biotech Australia Pty. Limited, Commonwealth Scientific and Industrial Research Organization
    Inventors: Phillip John Sharp, Barry Maxwell Wagland
  • Patent number: 5843710
    Abstract: Disclosed is the invention relates to proteins derived from parasitic nematodes which confer protective immunity against infection by parasitic nematodes, to nucleotide sequences encoding these proteins, to recombinant molecules containing such sequences to host cells transformed with such recombinant molecules and methods for the production of the nucleotide sequences recombinant molecules and hosts. The invention also relates to vaccines comprising proteins of the invention together with suitable carriers or diluents and to antibodies raised against proteins of the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Biotech Australia Pty. Limited and Csiro
    Inventors: Gary Stewart Cobon, Rosemary Ann Austen, Ian Joseph O'Donnell, Maurice Joseph Frenkel, William Peter Keith Kennedy, Keith William Savin, Barry Maxwell Wagland
  • Patent number: 5843706
    Abstract: The invention disclosed relates to proteins derived from parasitic nematodes that confer protective immunity against infection by parasitic nematodes, to nucleotide sequences encoding those proteins, to recombinant molecules containing such sequences, to host cells transformed with such recombinant molecules and methods for the production of the nucleotide sequences, recombinant molecules and hosts. The invention also relates to vaccines comprising proteins of the invention together with suitable carriers or diluents and to antibodies raised against proteins of the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignees: Biotechnology Australia Pty, Ltd., Commonwealth Scientific and Industrial Organization
    Inventors: Gary Stewart Cobon, Rosemary Ann Austen, Ian Joseph O'Donnell, Maurice Joseph Frenkel, William Peter Keith Kennedy, Keith William Savin, Barry Maxwell Wagland
  • Patent number: 5734035
    Abstract: Disclosed is a substantially purified antigen derived from a first parasitic nematode species which, when administered to a host animal, is capable of protecting the host animal from infestation by a second parasitic mematode species, wherein the first and second parasitic nematode species may be the same or different, and the antigen has an apparent molecular weight of 40 kD as determined by SDS-PAGE under reducing conditions.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 31, 1998
    Assignees: Biotech Australia Pty Limited, Commonwealth Scientific and Industrial Research Organisation
    Inventors: Phillip John Sharp, Barry Maxwell Wagland